#151821

Anti-BCL10 [151]

Please Enter Your Email ID
Email ID

Cat. #151821

Anti-BCL10 [151]

Cat. #: 151821

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Bcl10

Class: Monoclonal

Application: ELISA ; IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Ming-Qing Du

Institute: University College London (UCL)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-BCL10 [151]
  • Research fields: Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism
  • Clone: 151
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; WB
  • Description: BCL-10 is an apoptotic regulatory molecule, of approximately 31 kDa. It was identified through its direct involvement in t(1:14) (p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. In B-cell follicles, BCL10 has been shown to be expressed abundantly in the germinal center B cells, moderately in the marginal zone, but only weakly in mantle zone B cells. This differential expression is an indicator of its importance in maturation and malignant transformation of human B-cells. BCL-10 contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB.
  • Immunogen: Full-length recombinant BCL-10 protein
  • Isotype: IgG1 kappa
  • Myeloma used: NS0

Target Details

  • Target: Bcl10
  • Target background: BCL-10 is an apoptotic regulatory molecule, of approximately 31 kDa. It was identified through its direct involvement in t(1:14) (p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma. In B-cell follicles, BCL10 has been shown to be expressed abundantly in the germinal center B cells, moderately in the marginal zone, but only weakly in mantle zone B cells. This differential expression is an indicator of its importance in maturation and malignant transformation of human B-cells. BCL-10 contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB.

Applications

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Shen et al. 2003. Blood. 102(4):1553-4. PMID: 12900354.
  • Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma.
  • Ye et al. 2000. Am J Pathol. 157(4):1147-54. PMID: 11021819.
  • BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.
  • Du et al. 2000. Blood. 95(12):3885-90. PMID: 10845924.
  • BCL10 gene mutation in lymphoma.